Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8254 | 0.86 | NPC1 (0.56) | CA1CA2ALDH1A1TSHRMAPT | |
| Hydrochloric Acid SCHEMBL9032 | 0.85 | NPC1 (0.55) | CA1CA2ALDH1A1TSHRMAPT | |
| SCHEMBL7856 | 0.78 | NPC1 (0.56) | ALDH1A1TSHRMAPTKDM4ENPSR1 | |
| SCHEMBL30680218 | 0.78 | NPC1 (0.56) | ALDH1A1TSHRMAPTKDM4ENPSR1 | |
| SCHEMBL20576216 | 0.78 | CA1 (0.51) | CA1CA2MAPK1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL29651829 | 0.77 | NPC1 (0.55) | ALDH1A1TSHRMAPTKDM4ENPSR1 | |
| Hydrochloric Acid SCHEMBL9337 | 0.77 | NPC1 (0.55) | ALDH1A1TSHRMAPTKDM4ENPSR1 | |
| SCHEMBL9386966 | 0.76 | DRD3 (0.47) | CA1CA2SIGMAR1CYP19A1ALDH1A1 | |
| SCHEMBL8431294 | 0.75 | ALDH1A1 (0.50) | MAPK1ALDH1A1LMNATSHRHTT | |
| SCHEMBL8733 | 0.74 | CA1 (0.59) | CA1CA2MAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546402-B2 | Chromone derivatives, a process for their preparation and their therapeutic applications | SOKOLOFF PIERRE (FR) | 2013-10-01 | — | — | US | disclosed |
| EP-2470520-B1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PF MEDICAMENT (FR) | 2013-07-17 | — | — | EP | disclosed |
| EP-2470520-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | Pierre Fabre Medicament (FR) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157463-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PIERRE FABRE MEDICAMENT (FR) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027289-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PIERRE FABRE MEDICAMENT (FR) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157463-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | CHRNA3, CHRM3, VDR | CA1 4368/4885CA2 3671/4885SIGMAR1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.